How to test for prostate cancer
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Testing for Prostate Cancer: Methods and Insights
Prostate-Specific Antigen (PSA) Testing
PSA Screening Efficacy and Safety
Prostate-specific antigen (PSA) testing is a common method for screening prostate cancer. A systematic review and meta-analysis of randomized controlled trials involving 721,718 men found that PSA screening likely has no significant effect on all-cause mortality and may have a minimal impact on prostate-specific mortality. However, the benefits of PSA screening must be weighed against potential harms, including complications from biopsies and treatments, as well as the risk of overdiagnosis and overtreatment.
PSA and MRI Followed by Targeted Biopsy
Combining PSA testing with magnetic resonance imaging (MRI) and targeted biopsy can reduce the risk of overdiagnosis. A study involving 17,980 participants showed that MRI-targeted biopsy alone, compared to systematic biopsy, significantly reduced the diagnosis of clinically insignificant prostate cancer while maintaining the detection rate of clinically significant cancers. This approach also minimized serious adverse events.
Advanced Screening Techniques
Multiparametric MRI (mpMRI)
Multiparametric MRI (mpMRI) has emerged as a superior method for detecting clinically significant prostate cancer compared to traditional systematic biopsies. Studies have shown that mpMRI, combined with MR/TRUS fusion biopsy, improves the detection rate of significant cancers and reduces the overdiagnosis of low-risk cancers. This method is now recommended in clinical guidelines for its efficacy in initial cancer detection and prognosis assessment.
Risk Prediction Models and Biomarkers
Newer screening tools, such as the Stockholm3 model, which combines blood-based risk prediction with MRI-targeted biopsies, have shown promise in reducing unnecessary biopsies while maintaining the detection of significant cancers. Additionally, serum-based models like the 4Kscore® and the prostate health index (PHI), as well as urine-based biomarkers like PCA3, have demonstrated better accuracy than PSA alone in detecting significant cancers .
ExoDx Prostate (IntelliScore) Test
The ExoDx Prostate (IntelliScore) test is a noninvasive urine exosome-RNA assay that helps stratify patients for the risk of high-grade prostate cancer. This test has been validated across multiple studies and has shown superior performance in discriminating high-grade cancers from low-grade and benign conditions, potentially avoiding unnecessary biopsies.
Imaging Techniques
Micro-Ultrasound (MicroUS)
Micro-ultrasound (MicroUS) is a novel high-resolution imaging technology that integrates into the standard clinical workflow of prostate biopsy. Studies have indicated that MicroUS detection rates for clinically significant prostate cancer are comparable to those of mpMRI, suggesting its potential as a cost-effective alternative.
PSMA Hybrid Imaging
Prostate-specific membrane antigen (PSMA) hybrid imaging is particularly useful for staging high-risk prostate cancer and detecting recurrences. This imaging technique has shown high detection rates, especially in patients with elevated PSA levels, and is recommended for its accuracy in identifying lymphogenic and bony metastases.
Conclusion
Testing for prostate cancer involves a variety of methods, each with its own benefits and limitations. PSA testing remains a widely used initial screening tool, but its combination with advanced imaging techniques like mpMRI and targeted biopsy can enhance accuracy and reduce overdiagnosis. Emerging biomarkers and risk prediction models offer promising alternatives that improve the detection of clinically significant cancers while minimizing unnecessary procedures. As research continues, these methods are likely to evolve, providing more precise and patient-friendly screening options.
Sources and full results
Most relevant research papers on this topic